Last Update 13 Mar 26

Fair value Decreased 13%

DNA: Future Returns Will Hinge On Monetizing Autonomous Labs By 2026

Analysts have trimmed their average price target for Ginkgo Bioworks Holdings, with cuts from $14 to $12 and from $9 to $5, reflecting reduced revenue growth assumptions, a slightly lower fair value estimate, and a higher discount rate as they wait for clearer progress on monetizing autonomous labs after the biosecurity divestiture.

Analyst Commentary

Bullish Takeaways

Bullish analysts still see enough long term potential to maintain positive ratings, even as they trim price targets to US$12 from US$14.
They highlight companies in the diagnostic tools group with clear multi year frameworks and multiple avenues for upside to growth assumptions as better positioned, and place Ginkgo within that context.
Upcoming 2026 guidance updates are viewed as a key milestone that could help investors frame Ginkgo's role in any broader sector recovery.
For bullish analysts, the current valuation reset is viewed as a rebalancing of expectations rather than an abandonment of the longer term growth story.

Bearish Takeaways

Bearish analysts cut their price target to US$5 from US$9 and keep a negative stance on the shares, reflecting reduced confidence in near term execution.
The divestiture of the biosecurity business narrows the focus of the company and leaves guidance centered on cash burn, which some see as limiting visibility on revenue and earnings.
Cautious voices want clearer evidence that autonomous labs can be built out and monetized at scale before assigning higher valuation multiples.
The combination of a lower fair value estimate, reduced growth assumptions, and attention to cash burn keeps more conservative analysts focused on execution risk rather than upside potential.

What's in the News

Ginkgo Bioworks launched Ginkgo Cloud Lab, a browser based interface that lets researchers run their benchwork on the company's autonomous lab infrastructure, powered by modular Reconfigurable Automation Carts and an AI agent called EstiMate that checks protocol compatibility and provides transparent pricing (Key Developments).
The Cloud Lab launch is tied to Ginkgo's 2026 plan to move all R&D services onto Nebula, its autonomous lab in Boston, and to phase out traditional lab benches in favor of programmable robotic systems that are accessible to academia and industry users (Key Developments).
Ginkgo Bioworks and Invaio Sciences agreed to collaborate on microbial strains that can produce peptide based crop protection inputs through industrial scale fermentation, with Ginkgo optimizing strains and processes using its autonomous lab and Catalyst automation software (Key Developments).
Ginkgo Bioworks and OpenAI reported a preprint on an AI system, built on GPT 5 and Ginkgo's cloud lab, that autonomously designed, executed, and analyzed biological experiments in a closed loop workflow, with safeguards such as validation via Pydantic models before any experiment ran (Key Developments).
Ginkgo Bioworks is working with Carnegie Mellon University under an ARPA H POSEIDON program award to help develop an orally administered pill with tumor targeting sensors and an at home cancer screening device, applying its cell and enzyme engineering capabilities to new diagnostic tools (Key Developments).

Valuation Changes

Fair Value: Analyst fair value estimates moved from about $10.00 to about $8.67, which is a modest reduction in implied upside.
Discount Rate: The discount rate increased slightly from about 9.66% to about 10.29%, which generally points to a more cautious stance on risk.
Revenue Growth: Revenue growth assumptions shifted from about 2.71% growth to a 3.48% decline, indicating a more conservative view on the top line.
Net Profit Margin: Net profit margin expectations moved marginally from about 15.65% to about 15.52%, which is essentially flat in practical terms.
Future P/E: The future P/E multiple edged up from roughly 27.56x to 27.91x, suggesting only a very small change in how future earnings are being valued.

0 views

Key Takeaways

Overly optimistic revenue and margin expectations face obstacles from slow sector adoption, underused lab capacity, and challenges in monetizing new AI and data offerings.
Regulatory, geopolitical, and competitive pressures may limit long-term growth, especially as customer acquisition and core-product commoditization risks increase.
Transition to scalable platform, strong financial flexibility, and focus on automation and AI tools position Ginkgo for diversified growth, recurring revenues, and long-term competitive advantage.

Catalysts

About Ginkgo Bioworks Holdings

Develops a platform for cell programming in the United States.What are the underlying business or industry changes driving this perspective?

Investors may be overestimating the speed and magnitude by which Ginkgo's expansion into life science tools and automated lab systems will convert into sustainable revenue growth, given the company's reliance on adoption of novel general-purpose automation platforms in a historically slow-moving, risk-averse sector-potentially leading to overoptimistic revenue projections over the next several years.
The market appears to be assuming rapid margin expansion driven by automation and cost reductions, but substantial underutilized leased lab space and the time required to scale high-throughput automated workflows suggest persistent drag on net margins and a slower path to profitability than implied by the current valuation.
Ginkgo's data
and AI-driven service offerings are being positioned as major future growth catalysts, yet early-stage revenue contribution, unproven willingness of customers to pay for data/models rather than traditional services, and uncertainty in monetization models for proprietary datasets add risk to both revenue and earnings estimates.
Momentum in the sector around AI and lab automation is fueling investor enthusiasm, but this enthusiasm may overlook growing regulatory scrutiny and geopolitical headwinds, especially regarding biosecurity and cross-border biotech deals, creating long-term uncertainty around both revenue growth and cost structure.
Expectations for revenue diversification, particularly from expanding into academic and mid-tier markets with off-the-shelf reagent and CRO services, may be premature, given the need to overcome customer acquisition barriers, competition from established incumbents, and a possible commoditization of core offerings-all factors that could cap long-term revenue and compress margins if not navigated carefully.

Ginkgo Bioworks Holdings Earnings and Revenue Growth

Ginkgo Bioworks Holdings Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Ginkgo Bioworks Holdings's revenue will decrease by 10.2% annually over the next 3 years.
Analysts are not forecasting that Ginkgo Bioworks Holdings will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Ginkgo Bioworks Holdings's profit margin will increase from -136.6% to the average US Life Sciences industry of 14.2% in 3 years.
If Ginkgo Bioworks Holdings's profit margin were to converge on the industry average, you could expect earnings to reach $23.7 million (and earnings per share of $0.38) by about September 2028, up from $-315.2 million today. The analysts are largely in agreement about this estimate.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 38.5x on those 2028 earnings, up from -2.0x today. This future PE is greater than the current PE for the US Life Sciences industry at 29.1x.
Analysts expect the number of shares outstanding to grow by 4.41% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 8.54%, as per the Simply Wall St company report.

Ginkgo Bioworks Holdings Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Ginkgo's successful transition from a high-customization R&D solutions provider to a scalable life science tools and automation platform-alongside demonstrated early traction with academic and commercial customers-positions it to capitalize on increasing demand for automation and AI-enabled bioengineering, supporting revenue growth and expanding its total addressable market.
The company's early achievement of $250 million in annual cost savings, coupled with a significant cash position ($474 million) and no bank debt, provides financial flexibility and a strong margin of safety to invest in future growth initiatives, which may enhance earnings and support sustainable profit margin improvement.
Modular automation products and services, like Ginkgo's RAC systems, aim to address industry-wide inefficiencies by enabling scalable, general-purpose laboratory automation. This positions Ginkgo advantageously to benefit from secular trends of lab digitization and falling genomic and automation costs, creating recurring and diversified revenue streams over the long term.
Strategic expansion beyond traditional biotech industry customers, such as entry into the large academic research tools market, suggests increased customer diversification and risk mitigation, potentially leading to a more stable, higher-growth revenue base.
The company's emphasis on accumulating high-value biological datasets and developing AI-powered tools-along with willingness to enable data ecosystem development-could create a sustained competitive moat and unlock future data monetization or licensing revenues, supporting both top-line growth and improved long-term net margins.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $11.333 for Ginkgo Bioworks Holdings based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $16.0, and the most bearish reporting a price target of just $9.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $167.1 million, earnings will come to $23.7 million, and it would be trading on a PE ratio of 38.5x, assuming you use a discount rate of 8.5%.
Given the current share price of $11.33, the analyst price target of $11.33 is 0.0% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Ginkgo Bioworks Holdings?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Cost Reductions And New Partnerships Will Shape Profit Prospects By 2026